表紙
市場調査レポート

複雑性皮膚・軟部組織感染症:パイプライン分析

Complicated Skin And Skin Structure Infections (cSSSI) - Pipeline Review, H2 2015

発行 Global Markets Direct 商品コード 251542
出版日 ページ情報 英文 72 Pages
即納可能
価格
本日の銀行送金レート: 1USD=101.51円で換算しております。
Back to Top
複雑性皮膚・軟部組織感染症:パイプライン分析 Complicated Skin And Skin Structure Infections (cSSSI) - Pipeline Review, H2 2015
出版日: 2015年12月16日 ページ情報: 英文 72 Pages
概要

複雑性皮膚・軟部組織感染症(cSSSI)とは、一般的にバクテリアによって引き起こされる皮膚および関連組織の感染症です。これらの感染症は、感染潰瘍ややけど、膿瘍などのような深部の軟部組織にまでおよぶものがあり、大がかりな外科的処置が必要となります。症状は腫れ、挫傷、悪寒、脱力感などがあります。素因としては軽度の外傷や既往の皮膚疾患、不衛生、まれに低下した宿主免疫などが挙げられます。治療には抗生剤 を用います。

当レポートでは、複雑性皮膚・軟部組織感染症の治療薬開発パイプラインの現況と最新アップデートによる各開発段階の比較分析、企業や研究機関によって開発中の治療薬、治療薬の評価、後期段階および中止されたプロジェクトに関する情報などを最新のニュースや発表も交えて提供しています。

イントロダクション

  • 調査範囲
  • 複雑性皮膚・軟部組織感染症 (cSSSI) 概要

治療薬の開発

  • パイプライン製品;概要
  • パイプライン製品;比較分析

企業で開発中の治療薬

パイプライン製品の概況

  • 後期段階の製品
  • 臨床段階の製品
  • 初期段階の製品

企業で開発中の製品

治療薬開発に従事している企業

  • Cempra, Inc.
  • CrystalGenomics, Inc.
  • Debiopharm International S.A.
  • Dong-A Socio Group
  • Furiex Pharmaceuticals, Inc.
  • GlaxoSmithKline plc
  • Melinta Therapeutics, Inc
  • Microbion Corporation
  • Paratek Pharmaceuticals, Inc.
  • The Medicines Company

治療薬の評価

  • 単剤製品
  • 標的別
  • 作用機序別
  • 投与経路別
  • 分子タイプ別

薬剤プロファイル

  • acorafloxacin
  • Bismuth ethanedithiol
  • CG-400549
  • Debio-1450
  • Debio-1452
  • delafloxacin
  • fusidic acid
  • GSK-2140944
  • lanopepden
  • omadacycline
  • oritavancin diphosphate
  • Small Molecules to Inhibit DHFR for Infectious Deseases
  • tedizolid phosphate

最近のパイプライン動向

休止中のプロジェクト

開発が中止された製品

製品開発のマイルストーン

  • 主なニュースとプレスリリース

付録

図表

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC7465IDB

Summary

Global Markets Direct's, 'Complicated Skin And Skin Structure Infections (cSSSI) - Pipeline Review, H2 2015', provides an overview of the Complicated Skin And Skin Structure Infections (cSSSI)'s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Complicated Skin And Skin Structure Infections (cSSSI), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Complicated Skin And Skin Structure Infections (cSSSI) and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Complicated Skin And Skin Structure Infections (cSSSI)
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Complicated Skin And Skin Structure Infections (cSSSI) and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Complicated Skin And Skin Structure Infections (cSSSI) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Complicated Skin And Skin Structure Infections (cSSSI) pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products

Reasons to buy

  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Complicated Skin And Skin Structure Infections (cSSSI)
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Complicated Skin And Skin Structure Infections (cSSSI) pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Complicated Skin And Skin Structure Infections (cSSSI) Overview
  • Therapeutics Development
    • Pipeline Products for Complicated Skin And Skin Structure Infections (cSSSI) - Overview
  • Complicated Skin And Skin Structure Infections (cSSSI) - Therapeutics under Development by Companies
  • Complicated Skin And Skin Structure Infections (cSSSI) - Pipeline Products Glance
    • Late Stage Products
    • Clinical Stage Products
    • Early Stage Products
  • Complicated Skin And Skin Structure Infections (cSSSI) - Products under Development by Companies
  • Complicated Skin And Skin Structure Infections (cSSSI) - Companies Involved in Therapeutics Development
    • CrystalGenomics, Inc.
    • Debiopharm International S.A.
    • Dong-A Socio Group
    • GlaxoSmithKline Plc
    • Melinta Therapeutics, Inc
    • MicuRx Pharmaceuticals, Inc.
    • Motif Bio Plc
    • Phosphagenics Limited
  • Complicated Skin and Skin Structure Infections (cSSSI) - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • CG-400549 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Debio-1450 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Debio-1452 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • delafloxacin - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • gepotidacin mesylate - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • iclaprim mesylate - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • MRX-I - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecule for Complicated Skin and Skin Structure Infections - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecules to Inhibit DHFR for Infectious Diseases - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • tedizolid phosphate - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Complicated Skin And Skin Structure Infections (cSSSI) - Recent Pipeline Updates
  • Complicated Skin And Skin Structure Infections (cSSSI) - Dormant Projects
  • Complicated Skin and Skin Structure Infections (cSSSI) - Product Development Milestones
    • Featured News & Press Releases
      • Sep 29, 2015: Motif Announces Presentation of Two Posters on Iclaprim at ID Week 2015
      • Sep 03, 2015: FDA Grants Fast Track Designation for Iclaprim
      • Aug 24, 2015: Potent Efficacy of Iclaprim Confirmed in Independent Laboratory Study
      • Apr 30, 2014: Cubist to Present New Pipeline Data Of Tedizolid Phosphate At 2014 European Congress of Clinical Microbiology and Infectious Diseases
      • Oct 22, 2013: Cubist Announces Submission of New Drug Application for Investigational Antibiotic Tedizolid for Treatment of Serious Skin Infections
      • Sep 04, 2013: Affinium Pharmaceuticals Announces the Initiation of a Phase 1 Intravenous Clinical Trial of a New Antibiotic Prodrug
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Complicated Skin And Skin Structure Infections (cSSSI), H2 2015
  • Number of Products under Development by Companies, H2 2015
  • Comparative Analysis by Late Stage Development, H2 2015
  • Comparative Analysis by Clinical Stage Development, H2 2015
  • Comparative Analysis by Early Stage Development, H2 2015
  • Products under Development by Companies, H2 2015
  • Complicated Skin And Skin Structure Infections (cSSSI) - Pipeline by CrystalGenomics, Inc., H2 2015
  • Complicated Skin And Skin Structure Infections (cSSSI) - Pipeline by Debiopharm International S.A., H2 2015
  • Complicated Skin And Skin Structure Infections (cSSSI) - Pipeline by Dong-A Socio Group, H2 2015
  • Complicated Skin And Skin Structure Infections (cSSSI) - Pipeline by GlaxoSmithKline Plc, H2 2015
  • Complicated Skin And Skin Structure Infections (cSSSI) - Pipeline by Melinta Therapeutics, Inc, H2 2015
  • Complicated Skin And Skin Structure Infections (cSSSI) - Pipeline by MicuRx Pharmaceuticals, Inc., H2 2015
  • Complicated Skin And Skin Structure Infections (cSSSI) - Pipeline by Motif Bio Plc, H2 2015
  • Complicated Skin And Skin Structure Infections (cSSSI) - Pipeline by Phosphagenics Limited, H2 2015
  • Assessment by Monotherapy Products, H2 2015
  • Number of Products by Stage and Target, H2 2015
  • Number of Products by Stage and Mechanism of Action, H2 2015
  • Number of Products by Stage and Route of Administration, H2 2015
  • Number of Products by Stage and Molecule Type, H2 2015
  • Complicated Skin And Skin Structure Infections (cSSSI) Therapeutics - Recent Pipeline Updates, H2 2015
  • Complicated Skin And Skin Structure Infections (cSSSI) - Dormant Projects, H2 2015

List of Figures

  • Number of Products under Development for Complicated Skin And Skin Structure Infections (cSSSI), H2 2015
  • Number of Products under Development by Companies, H2 2015
  • Comparative Analysis by Late Stage Development, H2 2015
  • Comparative Analysis by Early Stage Products, H2 2015
  • Assessment by Monotherapy Products, H2 2015
  • Number of Products by Targets, H2 2015
  • Number of Products by Stage and Targets, H2 2015
  • Number of Products by Mechanism of Actions, H2 2015
  • Number of Products by Stage and Mechanism of Actions, H2 2015
  • Number of Products by Routes of Administration, H2 2015
  • Number of Products by Stage and Routes of Administration, H2 2015
  • Number of Products by Stage and Top 10 Molecule Types, H2 2015
Back to Top